Recombinant Human CD82 Fc Chimera Protein, CF

2 μg/lane of Recombinant Human CD82/Kai-1 Fc Chimera was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 53-65 kDa and 105-130 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CD82 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant CD82/Kai‑1 Fc Chimera is used at 5 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human TIMP-1 that produces 50% optimal binding response is 2.5-12.5 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CD82/Kai-1 protein
  

  MD	Human IgG1 (Pro100-Lys330)	IEGR	Human CD82 (Gly103-Gln225) Accession # P27701
  N-terminus			C-terminus

• Accession #: P27701
• N-terminal Sequence: Met
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 40.7 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 53-65 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD82 Fc Chimera Protein, CF

• CD82 antigenC33
• CD82 molecule
• CD82
• IA4
• IA4C33 antigen
• Inducible membrane protein R2
• KAI1
• KAI1GR15
• kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyteantigen, antigen detected by monoclonal and IA4))
• Metastasis suppressor Kangai-1
• R2
• SAR2
• SAR2tetraspanin-27
• ST6
• ST6tspan-27
• Suppressor of tumorigenicity 6 protein
• Tetraspanin-27
• TSPAN27
• Tspan-27
• TSPAN274F9

Background

CD82 antigen, also known as Kai-1, C33 and TSPAN27, is a widely expressed palmitoylated molecule of the tetraspanin superfamily (1, 2). The general architecture of tetraspanins contain four transmembrane domains, two extracellular loops, a small inner cytoplasmic loop, and intra-cellular N and C termini (1). One of the extracellular loops is termed the large extracellular loop (LEL) and it is responsible for interactions with binding partners such as integrins. Within the LEL, human CD82/Kai-1 shares 65% and 63%amino acid (aa) sequence identity with mouse and rat CD82/Kai-1, respectively. CD82/Kai-1 is a component of the promiscuous TIMP-1 interacting protein complex on the cell surface of human adenocarcinoma cells and gives insight into tumorigenic metastatic potential (3). CD82/Kai-1 suppresses EMT in prostate cancer cells adhered to fibronectin leading to reduced cell migration and invasiveness (4). CD82/Kai-1 function is important for muscle stem cell function in muscular disorders (5). Overexpression of CD82/Kai-1 suppresses growth, migration and invasion of oral cancer cells and may be considered as a potential therapeutic target in oral cancer (6).

1. Mazurov, D. et al. (2006) J. Biol. Chem. 282:3896.
2. Berditchevski, F. et al. 2001, J Cell Sci. 114:4143.
3. Zang, J. et al. (2017) Oncotarget. 8:6496.
4. Lee, J. et al. (2017) Oncotarget.  8:1641.
5. Alexander, MS. et al. (2016) Cell Stem Cell. 19:800.
6. Chai, J. et al. (2017) Mol Med. Rep. April; 15:1527.

Bioinformatics

• Uniprot:
  • P27701()